$HIMS (Hims & Hers Health, Inc.) — investor discussion on X

Hims & Hers Expands Australian Women's Health Platform

Launches Hers brand in Australia offering personalized treatments for weight, hormonal health and hair regrowth

Hims Peptide Regulatory Expectations Rise, X Signals Turn Bullish

Multiple X users discuss technicals and short pressure, $30 key inflection

8-K: Item 5.02

Hims Appoints Jon Franklin as Chief Accounting Officer

New finance leader brings experience from Rivian and PwC

Hims invests in Arboretum LifeSciences, expanding into precision medicine

Participates in Arboretum's $30M Series A, advancing genetic testing for common diseases

HIMS Slides 1.64% to $29.30

Zacks reports latest session close, reflecting recent market performance

Hims Option Activity and Subscriber Model Estimates After CFO Sale

Unusual options and subscriber/ARPU model estimates highlight Q3 focus

Hims advances peptide push: BPC-157 human trial starts

Arkansas RCT marks first US clinical trial for BPC-157, bolstering peptide strategy

HIMS Launches AI-Powered App Experience for Weight Loss Members

New feature uses treatment history and outcomes to create a feedback loop; CEO Elshenawy highlights personalization edge

Analysts expect HIMS Q3 net income positive, revenue forecast above $900M

Multiple sources forecast Q3 revenue up >50% YoY; profitability could trigger re-rating

J.P. Morgan re-initiates coverage on HIMS with Hold and $32 PT

Analyst sees Novo partnership offsetting GLP-1 headwinds, positive on vertical integration and brand scale

FDA Warning Escalates, HIMS Pressured but Q2 Results Strong

Q2 revenue up 38.2% to $753M, raises guidance, but FDA regulatory risk persists

HIMS Faces Securities Lawsuit, DJS Law Group Seeks Investors

Company announcement reveals lawsuit, potential disclosure issues, adding legal risk

Hims officially enters Australia, marking first Asia-Pacific expansion

Company announcement confirms entry via Eucalyptus acquisition, paving way for international growth

Hims & Hers shares drop 8% on Visa monitoring dispute

Multiple sources confirm Visa monitoring dispute; stock pressured, highlighting consumer payment risk

Hims weekly close at $33.78, bullish momentum builds

Analyst sees upside to $39 if $32 support holds, but customer complaints persist

Hims CEO Defends Against FTC Lawsuit, Says It Misunderstands Business

CEO publicly defends data sharing and subscription practices, notes GLP-1 price declines

Hims marks 5th listing anniversary; institutions boosted stakes in Q2

Multiple institutions disclosed Q2 additions, plus 5th anniversary celebration, raising market attention

Oscar CEO says in talks with Hims; Hims reiterates no insurance interest

Oscar CEO mentions talks with Hims, but Hims CEO has repeatedly said no interest in insurance; nature of any deal unclear

Q2 Beat and Raised Guidance, Analyst Maintains Buy on Hims

Revenue up 38% to $753.2M, raised outlook, though margin concerns noted.

Post Q2, Analysts Turn Bearish as Margin Concerns Persist

Strong revenue growth offset by margin compression and negative FCF, Sell rating issued

8-K: Item 2.02, Item 9.01

Hims Q2 Revenue Beats but Loss Widens, Shares Fall 7%

Revenue $753M up 40%, 300K net adds, but EPS loss $0.10 misses, margins pressured

Earnings report

Hims & Hers Q2 Earnings Approaching, Multiple Sources Flag

Multiple independent X accounts mention HIMS in earnings week previews, confirming imminent report

Baillie Gifford Initiates New Position in Hims with 750k Shares

Prominent long-term investor takes stake, signaling confidence

US FTC Sues Hims & Hers Over Health Data Sharing

Stock remains under pressure; investors eye FTC suit and FDA peptide rules impact.

Vanguard Capital Management Discloses 5.01% Stake in Hims

Following an internal reorganization in Jan 2026, Vanguard Capital Management now holds ~11.2M shares (5.01%), while Vanguard Group previously held 21M shares.